• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

p53错义变体R248Q的半衰期延长促进了其积累以及与野生型p53形成异源四聚体,从而发挥显性负效应。

The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect.

作者信息

Klemm Nancy, Schimmer Roman R, Konrad Nils K, Thelen Flavian, Fullin Jonas, Topçu Ebru, Koch Christian, Treacy Milena, Leventhal Matthew Joseph, Bühler Marco M, Lysenko Veronika, Theocharides Alexandre P A, Kurppa Kari J, Balabanov Stefan, Baubec Tuncay, Krivtsov Andrei V, Miller Peter G, Armstrong Scott A, Ebert Benjamin L, Manz Markus G, Nombela-Arrieta Cesar, Boettcher Steffen

机构信息

Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.

Dana-Farber Cancer Institute, Boston, Massachusetts.

出版信息

Cancer Res. 2025 Jun 2;85(11):1978-1996. doi: 10.1158/0008-5472.CAN-24-1136.

DOI:10.1158/0008-5472.CAN-24-1136
PMID:40163352
Abstract

Missense mutants of p53, such as the frequent hotspot variant R248Q, exert a dominant-negative effect (DNE) on wild-type (WT) p53 in cancer cells with monoallelic TP53 mutations. However, the precise functional and molecular mechanisms of the DNE have remained elusive due to a lack of appropriate model systems. In this study, we developed a variety of model systems, including CRISPR-edited human isogenic cell lines and transcriptional reporter cell lines, and targeted protein degradation assays that were combined with functional and molecular analyses to functionally characterize the DNE. Formation of heterotetramers between R248Q and WT p53 impaired proper WT p53 functionality by preventing DNA binding and subsequent target gene transactivation. Furthermore, the markedly increased protein half-life of R248Q led to supraphysiologic levels of R248Q, which was critically required for the DNE. Drug-induced targeted protein degradation of R248Q to lower the R248Q:WT ratio restored the transcriptional activity of WT p53, induced antiproliferative effects in cancer cells in vitro, and elicited strong therapeutic activity in vivo. Together, this study provides mechanistic insights into the DNE of p53 missense mutants and indicates that the DNE represents a promising therapeutic target. Significance: Heterotetramerization between R248Q mutant and wild-type p53 in conjunction with supraphysiologic p53R248Q accumulation underlies the dominant-negative effect, highlighting the need to develop pharmacologic strategies to decrease the elevated R248Q:WT ratio. See related commentary by Gencel-Augusto and Lozano, p. 1955.

摘要

p53的错义突变体,如常见的热点变体R248Q,在具有单等位基因TP53突变的癌细胞中对野生型(WT)p53发挥显性负效应(DNE)。然而,由于缺乏合适的模型系统,DNE的确切功能和分子机制仍不清楚。在本研究中,我们开发了多种模型系统,包括CRISPR编辑的人同基因细胞系和转录报告细胞系,以及与功能和分子分析相结合的靶向蛋白质降解试验,以从功能上表征DNE。R248Q与WT p53之间形成异源四聚体,通过阻止DNA结合和随后的靶基因反式激活,损害了WT p53的正常功能。此外,R248Q显著增加的蛋白质半衰期导致R248Q的超生理水平,这是DNE所必需的关键因素。药物诱导的R248Q靶向蛋白质降解以降低R248Q:WT比率,恢复了WT p53的转录活性,在体外诱导癌细胞的抗增殖作用,并在体内引发强大的治疗活性。总之,本研究提供了关于p53错义突变体DNE的机制见解,并表明DNE是一个有前景的治疗靶点。意义:R248Q突变体与野生型p53之间的异源四聚化以及超生理的p53R248Q积累是显性负效应的基础,突出了开发降低升高的R248Q:WT比率的药理学策略的必要性。见Gencel-Augusto和Lozano的相关评论,第1955页。

相似文献

1
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect.p53错义变体R248Q的半衰期延长促进了其积累以及与野生型p53形成异源四聚体,从而发挥显性负效应。
Cancer Res. 2025 Jun 2;85(11):1978-1996. doi: 10.1158/0008-5472.CAN-24-1136.
2
Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells.显性负性p53突变体R248Q增强口腔鳞状细胞癌细胞的运动和侵袭活性。
Biomed Res. 2019;40(1):37-49. doi: 10.2220/biomedres.40.37.
3
Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.Fn14 通过促进 Mdm2 介导的 p53-R248Q 泛素化和降解来克服高级别浆液性卵巢癌对顺铂的耐药性。
J Exp Clin Cancer Res. 2019 Apr 25;38(1):176. doi: 10.1186/s13046-019-1171-6.
4
Limited importance of the dominant-negative effect of TP53 missense mutations.TP53 错义突变的显性负效应的重要性有限。
BMC Cancer. 2011 Jun 13;11:243. doi: 10.1186/1471-2407-11-243.
5
Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth.一种与饮食相关的化合物苯乙基异硫氰酸酯使突变型p53重新激活,从而抑制肿瘤生长。
Cell Death Differ. 2016 Oct;23(10):1615-27. doi: 10.1038/cdd.2016.48. Epub 2016 Jun 3.
6
Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights.抑癌基因 p53 L1 环突变作为第二位点抑制因子,恢复致癌性 p53 突变的 DNA 结合:结构和生化见解。
Biochem J. 2010 Mar 29;427(2):225-36. doi: 10.1042/BJ20091888.
7
The P72R Polymorphism in R248Q/W p53 Mutants Modifies the Mutant Effect on Epithelial to Mesenchymal Transition Phenotype and Cell Invasion via CXCL1 Expression.R248Q/W p53 突变体中的 P72R 多态性通过 CXCL1 表达改变突变体对上皮间质转化表型和细胞侵袭的影响。
Int J Mol Sci. 2020 Oct 28;21(21):8025. doi: 10.3390/ijms21218025.
8
Targeted Degradation of Mutant p53 Reverses the Pro-oncogenic Dominant-Negative Effect.突变型p53的靶向降解逆转促癌显性负效应。
Cancer Res. 2025 Jun 2;85(11):1955-1956. doi: 10.1158/0008-5472.CAN-25-1054.
9
Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.p53突变体对野生型p53介导的反式激活的影响具有细胞类型依赖性。
Oncogene. 1995 Jun 1;10(11):2103-11.
10
Elucidating the Mechanisms of R248Q Mutation-Enhanced p53 Aggregation and Its Inhibition by Resveratrol.阐明 R248Q 突变增强 p53 聚集的机制及其被白藜芦醇抑制的机制。
J Phys Chem B. 2023 Sep 14;127(36):7708-7720. doi: 10.1021/acs.jpcb.3c04700. Epub 2023 Sep 4.

本文引用的文献

1
Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells.突变型 TP53 的失活而非激活功能对于广泛的癌细胞的增殖、存活和转移是关键的。
Cancer Discov. 2024 Feb 8;14(2):362-379. doi: 10.1158/2159-8290.CD-23-0402.
2
Fundamental immune-oncogenicity trade-offs define driver mutation fitness.基本的免疫肿瘤学权衡定义了驱动突变的适应性。
Nature. 2022 Jun;606(7912):172-179. doi: 10.1038/s41586-022-04696-z. Epub 2022 May 11.
3
Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes.
获得非整倍体导致突变型 p53 相关获得性功能表型。
Nat Commun. 2021 Aug 31;12(1):5184. doi: 10.1038/s41467-021-25359-z.
4
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide.基于来那度胺调控的可逆转 ON/OFF 开关嵌合抗原受体
Sci Transl Med. 2021 Jan 6;13(575). doi: 10.1126/scitranslmed.abb6295.
5
A dominant-negative effect drives selection of missense mutations in myeloid malignancies.显性负效应驱动髓系恶性肿瘤中错义突变的选择。
Science. 2019 Aug 9;365(6453):599-604. doi: 10.1126/science.aax3649.
6
Cancer therapeutic targeting using mutant-p53-specific siRNAs.利用突变型 p53 特异性 siRNA 进行癌症治疗靶向。
Oncogene. 2019 May;38(18):3415-3427. doi: 10.1038/s41388-018-0652-y. Epub 2019 Jan 14.
7
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.通过 CRBN 定义噻唑并苯并二氮杂卓类似物靶向的人类 C2H2 锌指去泛素化酶。
Science. 2018 Nov 2;362(6414). doi: 10.1126/science.aat0572.
8
Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor development.突变型 TRP53 发挥靶基因选择性显性负效应,驱动肿瘤发生。
Genes Dev. 2018 Nov 1;32(21-22):1420-1429. doi: 10.1101/gad.314286.118. Epub 2018 Oct 26.
9
Mutational processes shape the landscape of TP53 mutations in human cancer.突变过程塑造了人类癌症中 TP53 突变的景观。
Nat Genet. 2018 Oct;50(10):1381-1387. doi: 10.1038/s41588-018-0204-y. Epub 2018 Sep 17.
10
Putting p53 in Context.将p53置于背景中考虑。
Cell. 2017 Sep 7;170(6):1062-1078. doi: 10.1016/j.cell.2017.08.028.